Positives

• Patients on AXA1125 in a phase 2a Long COVID trial reported clinically and statistically significant drops in mental and physical fatigue scores after four weeks compared to placebo eClinicalMedicine.
  
  
• Every patient who started the trial completed it and none reported serious adverse effects from the orange-flavored amino acid powder University of Oxford.
  
  

Negatives

• Despite fatigue improvement, patients did not see any change in phosphocreatine recovery, the actual mitochondrial respiration measure the trial was designed to move PMC.
  
  
• Long COVID patients on Health Rising note that the trial only evaluated fatigue and did not address the breathlessness or cardiovascular symptoms many of them rate as more disabling Health Rising.
  
  

Hurdles & Side Effects

• AXA1125 is investigational only and not commercially available, so patients have no way to obtain it outside of trials University of Oxford.
  
  
• A patient interested in this approach must dissolve and drink the formulation twice daily, a regimen that proved acceptable in trial but has no community-access pathway eClinicalMedicine.